Solutions In… Artificial Intelligence
Is AI turning the tide for next-generation peptide therapeutics?
Maryam Mahdi | | Interview
Pharma is (slowly) being redefined by artificial intelligence (AI) and machine learning (ML) platforms. From clinical trials to the manufacture of drugs, these technologies give the industry the opportunity to enhance its practices and remove the risk of human error. And though many companies are beginning to embrace the potential advantages of AI, Mytide Therapeutics, a Boston-based biotech company, has integrated AI ever since its inception. Here, Dale Thomas, the company’s cofounder, tells us how they use AI for the discovery and development of peptide therapeutics, and shares his expectations for the company in 2020.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.